Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (NASDAQ: CODX) said its joint venture CoMira Diagnostics secured an industrial land allocation in Sudair Industrial City, Saudi Arabia, approved by MODON on April 2, 2026. The site is intended for a molecular diagnostics manufacturing facility; final lease hinges on site infrastructure completion.
The facility aims to localize production of molecular instruments and assays, support Saudi Vision 2030 objectives, and position CoMira among early domestic diagnostic manufacturers; the Co-Dx PCR platform remains subject to regulatory review.
Co-Diagnostics (NASDAQ: CODX) reported full year 2025 results and operational milestones on March 31, 2026. Revenue fell to $0.6M from $3.9M in 2024; operating expenses were $50.6M including an $18.9M intangible impairment. Net loss was $46.9M, or $35.25 per share; cash and securities totaled $11.9M.
Operationally, Co-Dx closed equity offerings raising $10.8M, secured a CDSCO license in India, began instrument and TB test shipments to India, advanced CoSara and CoMira joint ventures, and expanded IP with new patents.
Co-Diagnostics (Nasdaq: CODX) has shipped PCR Pro instruments, Co-Dx PCR MTB test kits and sample-prep devices to joint venture CoSara in India to enable clinical performance studies for a TB test aligned with new WHO 2026 guidance on near-point-of-care molecular testing and tongue swabs. The company also received a CDSCO license to manufacture and sell the PCR Pro instrument in India and says clinical study commencement is expected in the near term while U.S. regulatory review remains ongoing.
Co-Diagnostics (Nasdaq: CODX) expanded its CoSara joint venture commercial territory to include Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the South Asia addressable market to an estimated $13.0 billion. The move supports planned commercialization of the PCR Pro® point-of-care instrument and SARAGENE® tests, subject to regulatory approvals.
CoSara will evaluate regulatory pathways, build distribution channels, and host a virtual distributor session in Q2 2026 with an in-person training meeting planned later in summer 2026.
Co-Diagnostics (Nasdaq: CODX) will release its Q4 and full year 2025 financial results on Tuesday, March 31, 2026 after market close. A conference call and webcast to discuss results will be held the same day at 4:30 p.m. ET.
Management participants include Dwight Egan (CEO), Brian Brown (CFO) and Andrew Benson (Head of Investor Relations). The live webcast will be available at ir.co-dx.com and a replay will be posted on the company's website.
Co-Diagnostics (Nasdaq: CODX) will join a Utah delegation at Medical Korea 2026 in Seoul, March 19–22, 2026. Co-Dx will participate in a healthcare roundtable on March 19 and present its upcoming Co-Dx PCR point-of-care platform. Attendance is partly supported by a WTC Utah grant.
The Co-Dx PCR platform remains under regulatory review and is not yet available for sale.
Co-Diagnostics (Nasdaq: CODX) announced that the Japan Patent Office granted Japanese Patent No. 7797537 on March 12, 2026, titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis."
The patent, originally registered December 26, 2025, contains 34 claims covering the Co-Dx PCR Pro instrument, proprietary test cups, and core automated point-of-care PCR platform technologies, and follows a 2025 Australian patent. The company says this expands international IP protection while the platform remains subject to regulatory review and is not yet for sale.
Co-Diagnostics (Nasdaq: CODX) announced it regained compliance with Nasdaq listing rules, including the $1.00 bid price requirement, after receiving formal notice on March 9, 2026. Trading will resume on Nasdaq effective March 11, 2026. The company continues clinical performance studies and regulatory review of its Co-Dx PCR platform.
Co-Diagnostics (OTC: CODX) will exhibit at World Health Expo Labs Dubai February 10–13, 2026 at the Dubai World Trade Centre, Booth S17.C79.
The appearance follows formation of joint venture CoMira Diagnostics to localize manufacturing and distribution across Saudi Arabia and 18 MENA countries. The company is highlighting its upcoming Co-Dx PCR platform, currently in U.S. clinical studies and subject to regulatory review.
Co-Diagnostics (OTC: CODX) joint venture CoSara received a CDSCO Form MD-5 license on Feb 5, 2026, authorizing manufacture of the CoSara PCR Pro real-time PCR point-of-care instrument at its Ranoli, India facility for sale or distribution.
This instrument license is described as the final CDSCO instrument approval required before commercialization; the CoSara-branded PCR Pro will be manufactured and distributed in India and run with CoSara PCR test kits, which require separate regulatory clearance prior to use as IVDs.